UK regulator exposes systemic HRT supply chain failures: profit-driven delays in safety updates endanger patients globally

Indigenous knowledge systems often prioritise holistic, preventative approaches to hormonal health, such as plant-based remedies and community-based care, which are systematically excluded from Western regulatory frameworks. The censure of Theramex highlights how Western medicine’s profit-driven model devalues these alternatives, despite their lower risk and cultural relevance. For example, traditional Chinese medicine’s use of black cohosh for menopausal symptoms has been documented for centuries but remains sidelined in favour of synthetic HRT.

The scandal echoes historical precedents like the thalidomide disaster (1950s-60s), where profit motives led to inadequate safety testing, or the more recent opioid crisis, where regulatory capture enabled mass harm. The UK’s shift from public to privatised healthcare oversight in the 1980s laid the groundwork for today’s conflicts of interest, where regulators depend on industry-funded research. The 2008 financial crisis further eroded public trust in regulatory bodies, normalising underfunded oversight as a cost-saving measure.

Cross-culturally, menopause is framed differently: in Japan, it’s often seen as a natural transition without medicalisation, while in the US, it’s pathologised and monetised through HRT marketing. In many African and Indigenous communities, menopause is celebrated as a rite of passage, with herbal remedies used instead of pharmaceuticals. The censure of Theramex underscores how Western biomedical models dominate global health, often at the expense of culturally appropriate care.

Scientific evidence shows that delayed safety updates in HRT can lead to adverse events, including increased risks of blood clots, stroke, and cancer, particularly in long-term users. The censure highlights systemic flaws in pharmacovigilance, where post-market surveillance is underfunded and reactive rather than proactive. Independent studies have also shown that industry-funded trials often underreport risks, a pattern consistent with Theramex’s failures.

Artistic and spiritual traditions often depict menopause as a transformative phase, not a medical condition—e.g., the Māori concept of ‘whakapapa’ frames it as a connection to ancestral wisdom. The censure of Theramex reflects a broader cultural devaluation of this perspective, reducing women’s health to a commodity. Creative resistance, such as feminist art movements critiquing medicalisation, could challenge the dominant narrative.

Future scenarios must account for the growing demand for HRT amid aging populations, which could exacerbate regulatory failures if oversight remains underfunded. Climate change may also disrupt supply chains for hormone therapies, requiring decentralised, community-based alternatives. A shift toward open-source drug development and public funding of pharmacovigilance could mitigate these risks.

Marginalised groups—low-income women, trans and non-binary patients, and people of colour—are disproportionately affected by underregulated HRT due to systemic barriers in healthcare access. Trans patients, for example, often face gatekeeping in HRT prescriptions, while women of colour are more likely to receive outdated or unsafe formulations. The censure of Theramex reveals how these groups are treated as afterthoughts in a system designed for profit, not equity.